Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Asset Writedowns and Impairment (2016)

Tenax Therapeutics' Asset Writedowns and Impairment history spans 4 years, with the latest figure at $33.3 million for Q4 2016.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $33.3 million in Q4 2016 year-over-year; TTM through Dec 2016 was $33.3 million, a N/A change, with the full-year FY2016 number at $33.3 million, up 3114.44% from a year prior.
  • Asset Writedowns and Impairment hit $33.3 million in Q4 2016 for Tenax Therapeutics, up from $24110.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for TENX hit a ceiling of $33.3 million in Q4 2016 and a floor of $24110.0 in Q2 2013.
  • Historically, Asset Writedowns and Impairment has averaged $8.4 million across 3 years, with a median of $60423.5 in 2012.
  • Biggest five-year swings in Asset Writedowns and Impairment: plummeted 90.81% in 2012 and later decreased 13.14% in 2013.
  • Tracing TENX's Asset Writedowns and Impairment over 3 years: stood at $27758.0 in 2012, then dropped by 13.14% to $24110.0 in 2013, then skyrocketed by 137872.21% to $33.3 million in 2016.
  • Business Quant data shows Asset Writedowns and Impairment for TENX at $33.3 million in Q4 2016, $24110.0 in Q2 2013, and $27758.0 in Q2 2012.